Zai Lab (ZLAB) and argenx (ARGX) said Monday that China's National Medical Products Administration has approved Vyvgart Hytrulo to treat chronic inflammatory demyelinating polyneuropathy, a neuromuscular disorder, in adult patients.
The companies said the approval is supported by trial data from a subgroup analysis of Chinese participants which showed a 69% reduction in the risk of relapse with Vyvgart Hytrulo, compared to placebo.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.